MA32167B1 - Dérivés d'imidazo[1,2-b]pyridazine pour le traitement de maladies médiées par la tyrosine kinase c-met - Google Patents

Dérivés d'imidazo[1,2-b]pyridazine pour le traitement de maladies médiées par la tyrosine kinase c-met

Info

Publication number
MA32167B1
MA32167B1 MA33198A MA33198A MA32167B1 MA 32167 B1 MA32167 B1 MA 32167B1 MA 33198 A MA33198 A MA 33198A MA 33198 A MA33198 A MA 33198A MA 32167 B1 MA32167 B1 MA 32167B1
Authority
MA
Morocco
Prior art keywords
treatment
tyrosine kinase
imidazo
mediated diseases
kinase mediated
Prior art date
Application number
MA33198A
Other languages
Arabic (ar)
English (en)
Inventor
Pascal Furet
Clive Mccarthy
Joseph Schoepfer
Carsten Spanka
Melanie Stang
Frédéric Stauffer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39672115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32167(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32167B1 publication Critical patent/MA32167B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule (i) et des sels de ceux-ci, formule (i), dans lesquels les substituants sont comme défini dans la spécification, l'application d'un composé de formule (i) dans un procédé pour le traitement du corps humain ou animal, en particulier en ce qui concerne une maladie médiée par la tyrosine kinase c-met; l'utilisation d'un composé de formule (i) pour fabriquer un médicament pour le traitement de telles maladies; des compositions pharmaceutiques comprenant un composé de formule (i), facultativement en présence d'un partenaire de combinaison; des procédés pour la préparation d'un composé de formule (i).
MA33198A 2008-02-28 2010-09-24 Dérivés d'imidazo[1,2-b]pyridazine pour le traitement de maladies médiées par la tyrosine kinase c-met MA32167B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08152068 2008-02-28
PCT/EP2009/052302 WO2009106577A1 (fr) 2008-02-28 2009-02-26 Dérivés d’imidazo[1,2-b]pyridazine pour le traitement de maladies médiées par la tyrosine kinase c-met

Publications (1)

Publication Number Publication Date
MA32167B1 true MA32167B1 (fr) 2011-03-01

Family

ID=39672115

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33198A MA32167B1 (fr) 2008-02-28 2010-09-24 Dérivés d'imidazo[1,2-b]pyridazine pour le traitement de maladies médiées par la tyrosine kinase c-met

Country Status (25)

Country Link
US (1) US8822468B2 (fr)
EP (1) EP2265614A1 (fr)
JP (1) JP5576802B2 (fr)
KR (1) KR20100128305A (fr)
CN (1) CN102015716B (fr)
AR (1) AR070487A1 (fr)
AU (1) AU2009218459A1 (fr)
BR (1) BRPI0908504A2 (fr)
CA (1) CA2717034A1 (fr)
CL (1) CL2009000443A1 (fr)
CO (1) CO6300957A2 (fr)
CR (1) CR11620A (fr)
DO (1) DOP2010000263A (fr)
EA (1) EA201001365A1 (fr)
EC (1) ECSP10010427A (fr)
IL (1) IL207434A0 (fr)
MA (1) MA32167B1 (fr)
MX (1) MX2010009414A (fr)
NI (1) NI201000145A (fr)
PE (1) PE20091468A1 (fr)
SM (1) SMAP201000112A (fr)
TW (1) TW200940545A (fr)
UY (1) UY31676A1 (fr)
WO (1) WO2009106577A1 (fr)
ZA (1) ZA201005602B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
US8389526B2 (en) * 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
CA2771432A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composes d'oximes heterocycliques
EA030141B1 (ru) * 2009-12-31 2018-06-29 Хатчисон Медифарма Лимитед Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
US20110195066A1 (en) * 2010-02-05 2011-08-11 Auspex Pharmaceuticals, Inc. Quinoline inhibitors of tyrosine kinase
US20130315895A1 (en) * 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UY33597A (es) * 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012175591A1 (fr) * 2011-06-22 2012-12-27 Bayer Intellectual Property Gmbh Hétérocyclylaminoimidazopyridazines
CN103958509B (zh) * 2011-09-15 2015-12-23 诺华股份有限公司 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
CA2848809A1 (fr) 2011-09-15 2013-03-21 Novartis Ag 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituees en position 6 a activite tyrosine kinase
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
LT2925757T (lt) 2012-11-19 2017-12-27 Novartis Ag Junginiai ir kompozicijos, skirti parazitinių ligų gydymui
JP2016510764A (ja) 2013-03-07 2016-04-11 カリフィア バイオ, インク.Califia Bio, Inc. 混合系キナーゼ阻害剤および治療法
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
CN105326793A (zh) * 2014-08-06 2016-02-17 中美冠科生物技术（太仓）有限公司 一种包含c-Met激酶抑制剂的固体分散体及其制备方法和用途
AU2015366202B2 (en) * 2014-12-19 2020-01-02 Janssen Pharmaceutica Nv Heterocyclyl linked imidazopyridazine derivatives as PI3Kbeta inhibitors
KR20170095239A (ko) * 2014-12-19 2017-08-22 얀센 파마슈티카 엔.브이. ＰＩ３Ｋβ 저해제로서의 이미다조피리다진 유도체
CN109715631B (zh) 2016-09-16 2022-02-18 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） Traf 6抑制剂
US11185548B2 (en) * 2016-12-23 2021-11-30 Helmholtz Zentrum Munchen—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases
WO2018138050A1 (fr) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Dérivés hétérocycliques bicycliques condensés utilisés comme pesticides
US11584744B2 (en) * 2017-06-23 2023-02-21 University Of Washington Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them
JP7296992B2 (ja) * 2018-05-28 2023-06-23 エフ． ホフマン－ラ ロシュ アーゲー 細菌感染症の処置および予防のための新規オキソキノリジン化合物
CN120025336A (zh) * 2019-12-18 2025-05-23 加利福尼亚大学董事会 Lin28抑制剂和其使用方法
CN119081395B (zh) * 2024-09-07 2025-03-18 广东环塑众创实业有限公司 一种耐高温尼龙工程塑料及其制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489755A (en) 1966-08-03 1970-01-13 Pfizer & Co C Imidazo (1,2-b) pyridazines
GB8719368D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Heterocyclic compounds
FR2619818B1 (fr) * 1987-09-01 1990-01-12 Sanofi Sa Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2057089A1 (fr) 1990-12-07 1992-06-08 Eric E. Allen Derives de substitution de pyrazolopyrimidines and d'imidazopyridazines, antagonistes de l'angiotensine ii
CN1173975C (zh) 2000-04-27 2004-11-03 山之内制药株式会社 咪唑并吡啶衍生物
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
DE60326646D1 (de) 2002-12-18 2009-04-23 Vertex Pharma Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
AU2004255200A1 (en) 2003-06-30 2005-01-20 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
US7037909B2 (en) 2003-07-02 2006-05-02 Sugen, Inc. Tetracyclic compounds as c-Met inhibitors
CN1871008A (zh) 2003-10-21 2006-11-29 默克公司 用于治疗神经病变性疼痛的三唑并－哒嗪化合物和它们的衍生物
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
JP2007518823A (ja) 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
EP1713784A1 (fr) 2004-02-12 2006-10-25 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines et ligands associes des recepteurs de benzodiazepine
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
WO2006099972A1 (fr) 2005-03-23 2006-09-28 F. Hoffmann-La Roche Ag Derives d'acetylenyl-pyrazolo-pyrimidine comme antagonistes mglur2
US20090156617A1 (en) 2005-05-12 2009-06-18 Northrup Alan B Tyrosine kinase inhibitors
EP1910369A1 (fr) * 2005-07-29 2008-04-16 Astellas Pharma Inc. Hétérocycles fusionnés en tant qu inhibiteurs de lck
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
HRP20170103T1 (hr) 2005-12-21 2017-03-24 Janssen Pharmaceutica N.V. Triazolopiridazini kao modulatori tirozin kinaze
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
CA2651979A1 (fr) 2006-05-30 2007-12-06 Pfizer Products Inc. Derives de la triazolopyridazine
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8198448B2 (en) * 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
AU2007279595A1 (en) 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
EP2057164A1 (fr) 2006-08-07 2009-05-13 Incyte Corporation Utilisation de triazolotriazines en tant qu'inhibiteurs des kinases
WO2008030744A2 (fr) 2006-09-05 2008-03-13 Board Of Regents, The University Of Texas System Inhibiteurs de c-met et leurs utilisations
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
KR101083177B1 (ko) 2006-10-23 2011-11-11 에스지엑스 파마슈티컬스, 인코포레이티드 트리아졸로-피리다진 단백질 키나제 조정제
RS54510B1 (sr) 2006-11-22 2016-06-30 Incyte Holdings Corporation Imidazotriazini i imidazopirimidini kao inhibitori kinaze
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
US8125627B2 (en) 2007-04-27 2012-02-28 Alakai Defense Systems, Inc. Laser spectroscopy system
EP2170894A1 (fr) 2007-06-21 2010-04-07 Janssen Pharmaceutica N.V. Formes polymorphes et hydratées, sels et procédé de préparation de la 6-{difluoro[6-(1-méthyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]méthyl}quinoléine
EP2217601A1 (fr) * 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines utilisées comme qu'inhibiteurs de protéine kinases
US20110097189A1 (en) 2007-12-31 2011-04-28 Aaron Sandoval Boundary layer effect turbine
JP2009227599A (ja) 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体

Also Published As

Publication number Publication date
AU2009218459A1 (en) 2009-09-03
ECSP10010427A (es) 2010-09-30
CN102015716A (zh) 2011-04-13
UY31676A1 (es) 2009-09-30
TW200940545A (en) 2009-10-01
IL207434A0 (en) 2010-12-30
WO2009106577A1 (fr) 2009-09-03
CA2717034A1 (fr) 2009-09-03
MX2010009414A (es) 2010-09-24
NI201000145A (es) 2011-03-02
PE20091468A1 (es) 2009-10-22
US8822468B2 (en) 2014-09-02
BRPI0908504A2 (pt) 2015-08-11
CL2009000443A1 (es) 2010-09-10
JP2011513279A (ja) 2011-04-28
EA201001365A1 (ru) 2011-04-29
DOP2010000263A (es) 2010-09-30
KR20100128305A (ko) 2010-12-07
ZA201005602B (en) 2011-04-28
JP5576802B2 (ja) 2014-08-20
CO6300957A2 (es) 2011-07-21
US20090264406A1 (en) 2009-10-22
SMAP201000112A (it) 2010-11-12
CN102015716B (zh) 2014-09-17
EP2265614A1 (fr) 2010-12-29
CR11620A (es) 2010-10-08
AR070487A1 (es) 2010-04-07

Similar Documents

Publication Publication Date Title
MA32167B1 (fr) Dérivés d'imidazo[1,2-b]pyridazine pour le traitement de maladies médiées par la tyrosine kinase c-met
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
NO20063758L (no) Pyrazolo[1,5-A]pyrimidin-7-yl-amin derivater for anvendelse i behandling av proteinkinase avhengige sykdommer
ATE329596T1 (de) Phthalazinderivate zur behandlung von entzündlicher erkrankungen
JO3265B1 (ar) مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
EA200900388A1 (ru) Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
EP1973407A4 (fr) Composes spiro et procedes d utilisation
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
WO2007089857A3 (fr) Derives d'imidazole a substitution, compositions et procedes d'utilisation en tant qu'inhibiteurs de ptpase
BRPI0509069A (pt) compostos de imidazol para o tratamento de distúrbios neurodegenerativos
MY199552A (en) Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preapring the same
EA200870373A1 (ru) Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ
EA201101704A1 (ru) ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА
TW200613305A (en) Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
UA103617C2 (ru) Производные тиенопиридона как активаторы амр-активированной протеинкиназы (амрк)
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
TN2010000390A1 (en) Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
UA100390C2 (en) Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors